Basilea Pharmaceutica has reported positive top-line results from the Phase I study of its antibiotic BAL30072, used for the treatment of infections caused by multi-drug resistant Gram-negative bacteria.
The double-blind randomised clinical Phase I study demonstrated the safety, tolerability and pharmacokinetics of BAL30072 at all dose levels.
Basilea Pharmaceutica CEO Anthony Man said the results support the potential of BAL30072 as a new treatment option for severe and life-threatening infections caused by multi-drug resistant Gram-negative bacteria.
“We will be further advancing the phase I programme with this promising drug this year,” Man said.
BAL30072 is a siderophore, an iron-binding sulfactam antibiotic.